Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press1692910.36691/RJA16929ReviewsНаучные обзорыReview ArticlePharmacogenetics of psoriasis: predictors of the efficacy of anticytokine biological therapyФармакогенетика псориаза: предикторы эффективности антицитокиновой генно-инженерной биологической терапииhttps://orcid.org/0000-0002-0238-6563ShatokhinaEugenia A.ШатохинаЕвгения Афанасьевна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д-р мед. наук, профессор

e.a.shatokhina@gmail.comhttps://orcid.org/0000-0001-5313-0624EgoshinaIrina G.ЕгошинаИрина Геннадьевна
Russian Federation
gratis72@mail.ruhttps://orcid.org/0009-0004-3764-4034Bridan-RostovskayaAnna S.Бридан-РостовскаяАнна Сергеевна
Russian Federation
abridan@bk.ruhttps://orcid.org/0000-0002-5044-5265KruglovaLarisa S.КругловаЛариса Сергеевна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д-р мед. наук, профессор

kruglovals@mail.ruhttps://orcid.org/0000-0002-1285-7357ShatokhinMaksim N.ШатохинМаксим Николаевич
Russian Federation

MD, Dr. Sci. (Med.), Professor

д-р мед. наук, профессор

m.n.shatokhin@gmail.comCentral State Medical Academy of Department of Presidential AffairsЦентральная государственная медицинская академия Управления делами Президента Российской ФедерацииMedical Research and Education Centre of Lomonosov Moscow State UniversityМедицинский научно-образовательный центр Московского государственного университета имени М.В. ЛомоносоваKuzbass Clinical Skin and Venereological DispensaryКузбасский клинический кожно-венерологический диспансерRussian Medical Academy of Continuous Professional EducationРоссийская медицинская академия непрерывного профессионального образования03042024150420242111671762702202422032024Copyright ©; 2024, Pharmarus Print MediaCopyright ©; 2024, Фармарус Принт Медиа2024Pharmarus Print MediaФармарус Принт Медиаhttps://creativecommons.org/licenses/by-nc-nd/4.0/https://rusalljournal.ru/raj/article/view/16929

Psoriasis is a common chronic immune-mediated inflammatory inflammatory skin disease. The systemic nature of the inflammatory process, as well as the association with other diseases (psoriatic arthritis, inflammatory bowel disease, cardiovascular disease, depression, metabolic syndrome) significantly worsen the patient's quality of life, increasing the mortality curve.

Different groups of drugs are used in the treatment of psoriasis, but according to the latest scientific data, the most effective is genetically engineered biological therapy, which targets key cytokines of psoriasis immunopathogenesis. Although there are numerous and effective biologics therapy used for the treatment of psoriasis, primary and secondary non-responders are becoming increasingly common, and not all patients achieve remission in the long term, which has a negative impact on quality of life. Identification of genetic markers associated with response to therapy using pharmacogenetic studies is a high current issue, as this presents new opportunities for personalized medicine and will identify genetic markers for each drug group.

The review analyzes the available data from pharmacogenetic studies that have identified genes and their polymorphisms associated with response to biologics therapy.

Псориаз ― распространённое хроническое иммуноопосредованное воспалительное заболевание кожи. Системность воспалительного процесса, а также ассоциация с другими заболеваниями (псориатический артрит, воспалительные заболевания кишечника, сердечно-сосудистые заболевания, депрессия, метаболический синдром) значительно ухудшают качество жизни пациента, повышая кривую смертности.

В лечении псориаза используют разные группы препаратов, однако, согласно последним научным данным, наиболее эффективной является генно-инженерная биологическая терапия, которая прицельно воздействует на ключевые цитокины иммуннопатогенеза псориаза. Тем не менее, несмотря на многообразие и эффективность генно-инженерных биологических препаратов, назначаемых для лечения псориаза, всё чаще встречаются первичные и вторичные неответчики, к тому же не все пациенты достигают полной ремиссии в долгосрочной перспективе, что негативно влияет на качество их жизни. Такая гетерогенность обусловлена различными генетическими особенностями, поэтому актуальными остаются вопросы выявления генетических маркеров эффективности биологических препаратов, ассоциированных с ответом на терапию, решение которых посредством фармакогенетических исследований откроет новые возможности для персонифицированной медицины.

В обзоре проведён анализ имеющихся данных фармакогенетических исследований, с помощью которых были выявлены гены и их полиморфизмы, ассоциированные с ответом на генно-инженерную биологическую терапию.

pharmacogenetics of psoriasispharmacogenomicspsoriasisgeneticsgene polymorphismbiological therapypersonalized medicinesingle nucleotide polymorphismфармакогенетика псориазафармакогеномика псориазапсориазгенетикаполиморфизм геновгенно-инженерные биологические препаратыперсонализированная медицинаоднонуклеотидный полиморфизмKruglova LS, Bakulev AL, Korotaeva TV, Lila AM. Psoriasis. Moscow: GEOTAR-Media; 2022. 328 р. (In Russ).Круглова Л.С., Бакулев А.Л., Коротаева Т.В., Лила А.М. Псориаз. Москва: ГЭОТАР-Медиа, 2022. 328 с.Dhana A, Yen H, Yen H, Cho E. All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(5):1332–1343. doi: 10.1016/j.jaad.2018.12.037Dhana A., Yen H., Yen H., Cho E. All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis // J Am Acad Dermatol. 2019. Vol. 80, N 5. P. 1332–1343. doi: 10.1016/j.jaad.2018.12.037Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the U.K.: Cause-specific mortality in patients with severe psoriasis. Br J Dermatol. 2010;163(3):586–592. doi: 10.1111/j.1365-2133.2010.09941.xAbuabara K., Azfar R.S., Shin D.B., et al. Cause-specific mortality in patients with severe psoriasis: A population-based cohort study in the U.K.: Cause-specific mortality in patients with severe psoriasis // Br J Dermatol. 2010. Vol. 163, N 3. P. 586–592. doi: 10.1111/j.1365-2133.2010.09941.xSantus P, Rizzi M, Radovanovic D, et al. Psoriasis and respiratory comorbidities: The added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. BioMed Res Int. 2018;2018:3140682. doi: 10.1155/2018/3140682Santus P., Rizzi M., Radovanovic D., et al. Psoriasis and respiratory comorbidities: The added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy // BioMed Res Int. 2018. Vol. 2018. Р. 3140682. doi: 10.1155/2018/3140682Conic RR, Damiani G, Schrom KP, et al. Psoriasis and psoriatic arthritis cardiovascular disease endotypes identified by red blood cell distribution width and mean platelet volume. J Clin Med. 2020;9(1):186. doi: 10.3390/jcm9010186Conic R.R., Damiani G., Schrom K.P., et al. Psoriasis and psoriatic arthritis cardiovascular disease endotypes identified by red blood cell distribution width and mean platelet volume // J Clin Med. 2020. Vol. 9, N 1. P. 186. doi: 10.3390/jcm9010186Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases. J Am Acad Dermatol. 2017;76(3):377–390. doi: 10.1016/j.jaad.2016.07.064Takeshita J., Grewal S., Langan S.M., et al. Psoriasis and comorbid diseases // J Am Acad Dermatol. 2017. Vol. 76, N 3. P. 377–390. doi: 10.1016/j.jaad.2016.07.064Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: A comprehensive review. J Autoimmun. 2015;(64):66–73. doi: 10.1016/j.jaut.2015.07.008Harden J.L., Krueger J.G., Bowcock A.M. The immunogenetics of psoriasis: A comprehensive review // J Autoimmun. 2015. N 64. P. 66–73. doi: 10.1016/j.jaut.2015.07.008Berna-Rico E, Perez-Bootello J, de Aragon C, Gonzalez-Cantero A. Genetic Influence on treatment response in psoriasis: New insights into personalized medicine. Int J Mol Sci. 2023;24(12):9850. doi: 10.3390/ijms24129850Berna-Rico E., Perez-Bootello J., de Aragon C., Gonzalez-Cantero A. Genetic Influence on treatment response in psoriasis: New insights into personalized medicine // Int J Mol Sci. 2023. Vol. 24, N 12. P. 9850. doi: 10.3390/ijms24129850Lee YH, Song GG. Associations between interleukin-23R and interleukin-12B polymorphisms and psoriasis susceptibility: A meta-analysis. Immunol Investig. 2013;42(8):726–736. doi: 10.3109/08820139.2013.810241Lee Y.H., Song G.G. Associations between interleukin-23R and interleukin-12B polymorphisms and psoriasis susceptibility: A meta-analysis // Immunol Investig. 2013. Vol. 42, N 8. P. 726–736. doi: 10.3109/08820139.2013.810241Caputo V, Strafella C, Termine A, et al. Overview of the molecular determinants contributing to the expression of psoriasis and psoriatic arthritis phenotypes. J Cell Mol Med. 2020;24(23):13554–13563. doi: 10.1111/jcmm.15742Caputo V., Strafella C., Termine A., et al. Overview of the molecular determinants contributing to the expression of psoriasis and psoriatic arthritis phenotypes // J Cell Mol Med. 2020. Vol. 24, N 23. P. 13554–13563. doi: 10.1111/jcmm.15742Prieto-Pérez R, Cabaleiro T, Daudén E, et al. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis. 2013;2013:613086. doi: 10.1155/2013/613086Prieto-Pérez R., Cabaleiro T., Daudén E., et al. Genetics of psoriasis and pharmacogenetics of biological drugs // Autoimmune Dis. 2013. Vol. 2013. P. 613086. doi: 10.1155/2013/613086Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi: 10.3390/ijms20061475Rendon A., Schäkel K. Psoriasis pathogenesis and treatment // Int J Mol Sci. 2019. Vol. 20, N 6. P. 1475. doi: 10.3390/ijms20061475Jiménez MC, Ramírez PC, Martí SA, et al. Influence of genetic polymorphisms on response to biologics in moderate-to-severe psoriasis. J Pers Med. 2021;11(4):293. doi: 10.3390/jpm11040293Jiménez M.C., Ramírez P.C., Martí S.A., et al. Influence of genetic polymorphisms on response to biologics in moderate-to-severe psoriasis // J Pers Med. 2021. Vol. 11, N 4. P. 293. doi: 10.3390/jpm11040293Zhou X, Chen Y, Cui L, et al. Advances in the pathogenesis of psoriasis: From keratinocyte perspective. Cell Death Dis. 2022;13(1):81. doi: 10.1038/s41419-022-04523-3Zhou X., Chen Y., Cui L., et al. Advances in the pathogenesis of psoriasis: From keratinocyte perspective // Cell Death Dis. 2022. Vol. 13, N 1. P. 81. doi: 10.1038/s41419-022-04523-3Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6Sbidian E., Chaimani A., Garcia-Doval I., et al. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis // Cochrane Database Syst Rev. 2023. Vol. 7, N 7. P. CD011535. doi: 10.1002/14651858.CD011535.pub6Farhangian ME, Feldman SR. Immunogenicity of biologic treatments for psoriasis: Therapeutic consequences and the potential value of concomitant methotrexate. Am J Clin Dermatol. 2015;16(4):285–294. doi: 10.1007/s40257-015-0131-yFarhangian M.E., Feldman S.R. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate // Am J Clin Dermatol. 2015. Vol. 16, N 4. P. 285–294. doi: 10.1007/s40257-015-0131-yMuñoz-Aceituno E, Martos-Cabrera L, Ovejero-Benito MC, et al. Pharmacogenetics update on biologic therapy in psoriasis. Medicina. 2020;56(12):719. doi: 10.3390/medicina56120719Muñoz-Aceituno E., Martos-Cabrera L., Ovejero-Benito M.C., et al. Pharmacogenetics update on biologic therapy in psoriasis // Medicina. 2020. Vol. 56, N 12. P. 719. doi: 10.3390/medicina56120719Wang CY, Wang CW, Chen CB, et al. Pharmacogenomics on the treatment response in patients with psoriasis: An updated review. Int J Mol Sci. 2023;24(8):7329. doi: 10.3390/ijms24087329Wang C.Y., Wang C.W., Chen C.B., et al. Pharmacogenomics on the treatment response in patients with psoriasis: An updated review // Int J Mol Sci. 2023. Vol. 24, N 8. P. 7329. doi: 10.3390/ijms24087329Caputo V, Strafella C, Cosio T, et al. Pharmacogenomics: An update on biologics and small-molecule drugs in the treatment of psoriasis. Genes (Basel). 2021;12(9):1398. doi: 10.3390/genes12091398Caputo V., Strafella C., Cosio T., et al. Pharmacogenomics: An update on biologics and small-molecule drugs in the treatment of psoriasis // Genes (Basel). 2021. Vol. 12, N 9. P. 1398. doi: 10.3390/genes12091398Zhang X, Kuivenhoven JA, Groen AK. Forward individualized medicine from personal genomes to interactomes. Front Physiol. 2015;(6):364. doi: 10.3389/fphys.2015.00364Zhang X., Kuivenhoven J.A., Groen A.K. Forward individualized medicine from personal genomes to interactomes // Front Physiol. 2015. N 6. P. 364. doi: 10.3389/fphys.2015.00364Dand N, Mahil SK, Capon F, et al. Psoriasis and genetics. Acta Derm Venereol. 2020;100(3):adv00030. doi: 10.2340/00015555-3384Dand N., Mahil S.K., Capon F., et al. Psoriasis and genetics // Acta Derm Venereol. 2020. Vol. 100, N 3. P. adv00030. doi: 10.2340/00015555-3384Yan D, Gudjonsson JE, Le S, et al. New frontiers in psoriatic disease research, part I: Genetics, environmental triggers, immunology, pathophysiology, and precision medicine. J Invest Dermatol. 2021;141(9):2112–2122.e3. doi: 10.1016/j.jid.2021.02.764Yan D., Gudjonsson J.E., Le S., et al. New frontiers in psoriatic disease research, part I: Genetics, environmental triggers, immunology, pathophysiology, and precision medicine // J Invest Dermatol. 2021. Vol. 141, N 9. P. 2112–2122.e3. doi: 10.1016/j.jid.2021.02.764Coto-Segura P, González-Lara L, Batalla A, et al. NFKBIZ and CW6 in adalimumab response among psoriasis patients: Genetic association and alternative transcript analysis. Mol Diagn Ther. 2019;23(5):627–633. doi: 10.1007/s40291-019-00409-xCoto-Segura P., González-Lara L., Batalla A., et al. NFKBIZ and CW6 in adalimumab response among psoriasis patients: Genetic association and alternative transcript analysis // Mol Diagn Ther. 2019. Vol. 23, N 5. P. 627–633. doi: 10.1007/s40291-019-00409-xGallo E, Cabaleiro T, Román M, et al. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: A case-control study. Br J Dermatol. 2013;169(4):819–829. doi: 10.1111/bjd.12425Gallo E., Cabaleiro T., Román M., et al. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: A case-control study // Br J Dermatol. 2013. Vol. 169, N 4. P. 819–829. doi: 10.1111/bjd.12425Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120–2130. doi: 10.1016/j.jaci.2018.11.038Dand N., Duckworth M., Baudry D., et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis // J Allergy Clin Immunol. 2019. Vol. 143, N 6. P. 2120–2130. doi: 10.1016/j.jaci.2018.11.038Masouri S, Stefanaki I, Ntritsos G, et al. Pharmacogenetic study of psoriasis risk variants in a greek population and prediction of responses to anti-TNF-α and anti-IL-12/23 agents. Mol Diagn Ther. 2016;20(3):221–225. doi: 10.1007/s40291-016-0198-zMasouri S., Stefanaki I., Ntritsos G., et al. Pharmacogenetic study of psoriasis risk variants in a greek population and prediction of responses to anti-TNF-α and anti-IL-12/23 agents // Mol Diagn Ther. 2016. Vol. 20, N 3. P. 221–225. doi: 10.1007/s40291-016-0198-zPrieto-Pérez R, Solano-López G, Cabaleiro T, et al. Polymorphisms associated with age at onset in patients with moderate-to-severe plaque psoriasis. J Immunol Res. 2015;2015:101879. doi: 10.1155/2015/101879Prieto-Pérez R., Solano-López G., Cabaleiro T., et al. Polymorphisms associated with age at onset in patients with moderate-to-severe plaque psoriasis // J Immunol Res. 2015. Vol. 2015. P. 101879. doi: 10.1155/2015/101879Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, et al. Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis. Pharmacogenomics J. 2017;18(7):631–638. doi: 10.2217/pgs-2017-0014Ovejero-Benito M.C., Prieto-Pérez R., Llamas-Velasco M., et al. Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis // Pharmacogenomics J. 2017. Vol. 18, N 7. P. 631–638. doi: 10.2217/pgs-2017-0014Guarene M, Pasi A, Bolcato V, et al. The presence of HLA-ABw4-80I KIR ligands could predict “difficult-to-treat” psoriasis and poor response to etanercept. Mol Diagn Ther. 2018;22(4):471–474. doi: 10.1007/s40291-018-0345-9Guarene M., Pasi A., Bolcato V., et al. The presence of HLA-ABw4-80I KIR ligands could predict “difficult-to-treat” psoriasis and poor response to etanercept // Mol Diagn Ther. 2018. Vol. 22, N 4. P. 471–474. doi: 10.1007/s40291-018-0345-9Ovejero-Benito MC, Muñoz-Aceituno E, Reolid A, et al. Pharmacogenetics and pharmacogenomics in moderate-to-severe psoriasis. Am J Clin Dermatol. 2018;19(2):209–222. doi: 10.1007/s40257-017-0322-9Ovejero-Benito M.C., Muñoz-Aceituno E., Reolid A., et al Pharmacogenetics and pharmacogenomics in moderate-to-severe psoriasis // Am J Clin Dermatol. 2018. Vol. 19, N 2. P. 209–222. doi: 10.1007/s40257-017-0322-9Song GG, Seo YH, Kim JH, et al Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn’s disease: A meta-analysis. Pharmacogenomics. 2015;16(12):1427–1437. doi: 10.2217/pgs.15.90Song G.G., Seo Y.H., Kim J.H., et al Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn’s disease: A meta-analysis // Pharmacogenomics. 2015. Vol. 16, N 12. P. 1427–1437. doi: 10.2217/pgs.15.90Chen W, Xu H, Wang X, et al The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis. Int Immunopharmacol. 2015;28(1):146–153. doi: 10.1016/j.intimp.2015.05.049Chen W., Xu H., Wang X., et al The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis // Int Immunopharmacol. 2015. Vol. 28, N 1. P. 146–153. doi: 10.1016/j.intimp.2015.05.049Vasilopoulos Y, Manolika M, Zafiriou E, et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the greek population. Mol Diagn Ther. 2012;16(1):29–34. doi: 10.1007/BF03256427Vasilopoulos Y., Manolika M., Zafiriou E., et al. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to Anti-TNF therapy in psoriasis patients in the greek population // Mol Diagn Ther. 2012. Vol. 16, N 1. P. 29–34. doi: 10.1007/BF03256427González-Lara L, Batalla A, Coto E, et al. The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in psoriasis patients. Arch Dermatol Res. 2015;307(5):405–412. doi: 10.1007/s00403-014-1533-zGonzález-Lara L., Batalla A., Coto E., et al. The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in psoriasis patients // Arch Dermatol Res. 2015. Vol. 307, N 5. P. 405–412. doi: 10.1007/s00403-014-1533-zBucalo A, Rega F, Zangrilli A, et al. Paradoxical psoriasis induced by anti-TNFα treatment: Evaluation of disease-specific clinical and genetic markers. Int J Mol Sci. 2020;21(21):7873. doi: 10.3390/ijms21217873Bucalo A., Rega F., Zangrilli A., et al. Paradoxical psoriasis induced by anti-TNFα treatment: Evaluation of disease-specific clinical and genetic markers // Int J Mol Sci. 2020. Vol. 21, N 21. P. 7873. doi: 10.3390/ijms21217873Cabaleiro T, Prietoperez R, Navarro RM, et al. Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis. Pharmacogenom J. 2016;16(4):336–340. doi: 10.1038/tpj.2015.53Cabaleiro T., Prietoperez R., Navarro R.M., et al. Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis // Pharmacogenom J. 2016. Vol. 16, N 4. P. 336–340. doi: 10.1038/tpj.2015.53Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker Ustekinumab. Br J Dermatol. 2013;169(2):458–463. doi: 10.1111/bjd.12331Talamonti M., Botti E., Galluzzo M., et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab // Br J Dermatol. 2013. Vol. 169, N 2. P. 458–463. doi: 10.1111/bjd.12331Raposo I, Carvalho C, Bettencourt A, et al. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to Ustekinumab. Eur J Dermatol. 2017;27(5):528–530. doi: 10.1684/ejd.2017.3071Raposo I., Carvalho C., Bettencourt A., et al. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab // Eur J Dermatol. 2017. Vol. 27, N 5. P. 528–530. doi: 10.1684/ejd.2017.3071Prieto-Pérez R, Llamas-Velasco M, Cabaleiro T, et al. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis. Pharmacogenomics J. 2017;18(2):157–164. doi: 10.2217/pgs-2016-0122Prieto-Pérez R., Llamas-Velasco M., Cabaleiro T., et al. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis // Pharmacogenomics J. 2017. Vol. 18, N 2. P. 157–164. doi: 10.2217/pgs-2016-0122Loft ND, Skov L, Iversen L, et al. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics J. 2018;18(3):494–500. doi: 10.1038/tpj.2017.31Loft N.D., Skov L., Iversen L., et al. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis // Pharmacogenomics J. 2018. Vol. 18, N 3. P. 494–500. doi: 10.1038/tpj.2017.31Connell WT, Hong J, Liao W, et al. Genome-wide association study of ustekinumab response in psoriasis. Front Immunol. 2021;(12):815121. doi: 10.3389/fimmu.2021.815121Connell W.T., Hong J., Liao W., et al. Genome-wide association study of ustekinumab response in psoriasis // Front Immunol. 2021. N 12. Р. 815121. doi: 10.3389/fimmu.2021.815121Morelli M, Galluzzo M, Madonna S, et al. HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. Expert Opin Biol Ther. 2021;21(2):259–270. doi: 10.1080/14712598.2021.1862082Morelli M., Galluzzo M., Madonna S., et al. HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis // Expert Opin Biol Ther. 2021. Vol. 21, N 2. P. 259–270. doi: 10.1080/14712598.2021.1862082Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs. 2016;8(3):536–550. doi: 10.1080/19420862.2015.1136761Karle A., Spindeldreher S., Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity // MAbs. 2016. Vol. 8, N 3. P. 536–550. doi: 10.1080/19420862.2015.1136761Papini M, Cusano F, Romanelli M, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: Results from extension phase of the SUPREME study. Br J Dermatol. 2019;181(2):413–414. doi: 10.1111/bjd.18013Papini M., Cusano F., Romanelli M., et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: Results from extension phase of the SUPREME study // Br J Dermatol. 2019. Vol. 181, N 2. P. 413–414. doi: 10.1111/bjd.18013Lande R, Botti E, Jandus C, et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014;(5):5621. doi: 10.1038/ncomms6621Lande R., Botti E., Jandus C., et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis // Nat Commun. 2014. N 5. P. 5621. doi: 10.1038/ncomms6621Zhu H, Lou F, Yin Q, et al. RIG-I antiviral signaling drives interleukin-23 production and psoriasis-like skin disease. EMBO Mol Med. 2017;9(5):589–604. doi: 10.15252/emmm.201607027Zhu H., Lou F., Yin Q., et al. RIG-I antiviral signaling drives interleukin-23 production and psoriasis-like skin disease // EMBO Mol Med. 2017. Vol. 9, N 5. P. 589–604. doi: 10.15252/emmm.201607027Ishizaki M, Akimoto T, Muromoto R, et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Iimmunol. 2011;187(1):181–189. doi: 10.4049/jimmunol.1003244Ishizaki M., Akimoto T., Muromoto R., et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo // J Iimmunol. 2011. Vol. 187, N 1. P. 181–189. doi: 10.4049/jimmunol.1003244Van Vugt L. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: Results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020;34(1):112–118. doi: 10.1111/jdv.15787Van Vugt L. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the 17A gene: Results from a multicentre study of four European psoriasis cohorts // J Eur Acad Dermatol Venereol. 2020. Vol. 34, N 1. P. 112–118. doi: 10.1111/jdv.15787Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605–1613. doi: 10.4049/jimmunol.1800013Hawkes J.E., Yan B.Y., Chan T.C., Krueger J.G. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis // J Immunol. 2018. Vol. 201, N 6. P. 1605–1613. doi: 10.4049/jimmunol.1800013Cheuk S, Wikén M, Blomqvist L, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014;192(7):3111–3120. doi: 10.4049/jimmunol.1302313Cheuk S., Wikén M., Blomqvist L., et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis // J Immunol. 2014. Vol. 192, N 7. P. 3111–3120. doi: 10.4049/jimmunol.1302313Clark RA. Resident memory T cells in human health and disease. Sci Transl Med. 2015;7(269):269rv1. doi: 10.1126/scitranslmed.3010641Clark R.A. Resident memory T cells in human health and disease // Sci Transl Med. 2015. Vol. 7, N 269. P. 269rv1. doi: 10.1126/scitranslmed.3010641Loras A, Gil-Barrachina M, Hernando B, et al. Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to-severe psoriasis. Exp Dermatol. 2024;33(1):e15003. doi: 10.1111/exd.15003Loras A., Gil-Barrachina M., Hernando B., et al. Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to-severe psoriasis // Exp Dermatol. 2024. Vol. 33, N 1. P. e15003. doi: 10.1111/exd.15003